ALKS just reported Q2 results and the Street's reaction tells a split story: analysts are raising targets with unusual conviction, yet the stock fell 4.4% on the week to $50.50, leaving it well below where many of those fresh targets now sit.
The analyst activity this week has been the most directionally consistent in months. Multiple firms lifted targets immediately following earnings. Piper Sandler made the boldest move, raising its target from $43 to $65 while reiterating Overweight. Baird went from $48 to $58, also keeping its Outperform. JP Morgan — which only reinstated coverage two weeks ago at Neutral with a $60 target — nudged that to $61 on Tuesday, a modest move but notable given the timing. The picture isn't unanimous: Bank of America downgraded to Underperform late last month with a $38 target, a position that now stands as the clear outlier against a consensus mean of $56. The Street is broadly constructive, but BofA's $38 target suggests at least one major firm sees meaningful downside from here — roughly 25% below the current price.
Short positioning adds a wrinkle to the bullish analyst story. Bears have been covering, not building. Short interest fell by roughly 16% over both the past week and the past month, dropping from around 18.4 million shares in early July to 14.3 million, bringing SI to 8.7% of the free float — elevated in absolute terms but clearly in retreat. The borrow market confirms there is no squeeze pressure: availability is running at 549%, meaning roughly five-and-a-half times as many shares are available to borrow as are currently shorted, well above the 52-week minimum availability of 329%. Cost to borrow is just 0.44%, near its lowest level of the month. Shorts are leaving quietly and cheaply — there is no sign of a forced unwind.
Options traders are leaning bullish, reinforcing the direction of short covering. The put/call ratio has dropped to 0.56, nearly two standard deviations below its 20-day average of 0.69 — the most call-heavy reading in weeks. Three weeks ago the ratio was above 0.77; since earnings were announced last week, demand for downside protection has eroded sharply. The combination of short covering and call-side options demand suggests market participants are repositioning toward the bull case rather than hedging against further weakness.
The fundamental case rests on the orexin pipeline, specifically alixorexton for sleep disorders, which has driven an extraordinary year-to-date run of over 80%. EPS momentum ranks in the 99th percentile on a 90-day basis, and EPS surprise ranks equally high — the company has been consistently beating estimates. The P/E multiple has compressed about 7 points over 30 days to roughly 34x, a function of the price pull-back rather than deteriorating earnings expectations. Against that backdrop, BofA's bear case on partnership dependency and competitive risk in an unproven sleep disorder market is the one dissenting voice worth monitoring closely.
Peers held up better this week. INCY gained 10.7% on the week, HALO rose 6.2%, and ACAD added 2.3% — all outperforming ALKS's 4.4% decline. Whether that underperformance reflects post-earnings digestion or something more concerning about alixorexton's reception is the central question heading into the next catalyst: Q3 results are scheduled for October 29.
See the live data behind this article on ORTEX.
Open ALKS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
